These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 18281484)

  • 1. ADAM15 supports prostate cancer metastasis by modulating tumor cell-endothelial cell interaction.
    Najy AJ; Day KC; Day ML
    Cancer Res; 2008 Feb; 68(4):1092-9. PubMed ID: 18281484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the disintegrin metalloproteinase ADAM15 in prostate cancer progression.
    Lucas N; Day ML
    J Cell Biochem; 2009 Apr; 106(6):967-74. PubMed ID: 19229865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A disintegrin and metalloproteinase 15-mediated glycocalyx shedding contributes to vascular leakage during inflammation.
    Yang X; Meegan JE; Jannaway M; Coleman DC; Yuan SY
    Cardiovasc Res; 2018 Nov; 114(13):1752-1763. PubMed ID: 29939250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADAM15 expression is downregulated in melanoma metastasis compared to primary melanoma.
    Ungerer C; Doberstein K; Bürger C; Hardt K; Boehncke WH; Böhm B; Pfeilschifter J; Dummer R; Mihic-Probst D; Gutwein P
    Biochem Biophys Res Commun; 2010 Oct; 401(3):363-9. PubMed ID: 20851104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADAM15 targets MMP9 activity to promote lung cancer cell invasion.
    Dong DD; Zhou H; Li G
    Oncol Rep; 2015 Nov; 34(5):2451-60. PubMed ID: 26323669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADAM15 Is Functionally Associated with the Metastatic Progression of Human Bladder Cancer.
    Lorenzatti Hiles G; Bucheit A; Rubin JR; Hayward A; Cates AL; Day KC; El-Sawy L; Kunju LP; Daignault S; Lee CT; Liebert M; Hussain M; Day ML
    PLoS One; 2016; 11(3):e0150138. PubMed ID: 26930657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A disintegrin and metalloproteinase 15 contributes to atherosclerosis by mediating endothelial barrier dysfunction via Src family kinase activity.
    Sun C; Wu MH; Lee ES; Yuan SY
    Arterioscler Thromb Vasc Biol; 2012 Oct; 32(10):2444-51. PubMed ID: 22904271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease.
    Kuefer R; Day KC; Kleer CG; Sabel MS; Hofer MD; Varambally S; Zorn CS; Chinnaiyan AM; Rubin MA; Day ML
    Neoplasia; 2006 Apr; 8(4):319-29. PubMed ID: 16756724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells.
    Desai B; Rogers MJ; Chellaiah MA
    Mol Cancer; 2007 Mar; 6():18. PubMed ID: 17343740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.
    Burdelski C; Fitzner M; Hube-Magg C; Kluth M; Heumann A; Simon R; Krech T; Clauditz T; Büscheck F; Steurer S; Wittmer C; Hinsch A; Luebke AM; Jacobsen F; Minner S; Tsourlakis MC; Beyer B; Steuber T; Thederan I; Sauter G; Izbicki J; Schlomm T; Wilczak W
    Neoplasia; 2017 Apr; 19(4):279-287. PubMed ID: 28282546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADAM15 suppresses cell motility by driving integrin alpha5beta1 cell surface expression via Erk inactivation.
    Chen Q; Meng LH; Zhu CH; Lin LP; Lu H; Ding J
    Int J Biochem Cell Biol; 2008; 40(10):2164-73. PubMed ID: 18387333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularization.
    Xie B; Shen J; Dong A; Swaim M; Hackett SF; Wyder L; Worpenberg S; Barbieri S; Campochiaro PA
    FASEB J; 2008 Aug; 22(8):2775-83. PubMed ID: 18381816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-147b regulates vascular endothelial barrier function by targeting ADAM15 expression.
    Chatterjee V; Beard RS; Reynolds JJ; Haines R; Guo M; Rubin M; Guido J; Wu MH; Yuan SY
    PLoS One; 2014; 9(10):e110286. PubMed ID: 25333931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADAM 15 is an adhesion receptor for platelet GPIIb-IIIa and induces platelet activation.
    Langer H; May AE; Bültmann A; Gawaz M
    Thromb Haemost; 2005 Sep; 94(3):555-61. PubMed ID: 16268472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.
    Li Y; Kucuk O; Hussain M; Abrams J; Cher ML; Sarkar FH
    Cancer Res; 2006 May; 66(9):4816-25. PubMed ID: 16651437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pristimerin Inhibits Prostate Cancer Bone Metastasis by Targeting PC-3 Stem Cell Characteristics and VEGF-Induced Vasculogenesis of BM-EPCs.
    Huang S; He P; Peng X; Li J; Xu D; Tang Y
    Cell Physiol Biochem; 2015; 37(1):253-68. PubMed ID: 26302893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell adhesion-induced transient interaction of ADAM15 with poly(A) binding protein at the cell membrane colocalizes with mRNA translation.
    Böhm BB; Fehrl Y; Janczi T; Schneider N; Burkhardt H
    PLoS One; 2018; 13(9):e0203847. PubMed ID: 30265671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADAM15 overexpression in NIH3T3 cells enhances cell-cell interactions.
    Herren B; Garton KJ; Coats S; Bowen-Pope DF; Ross R; Raines EW
    Exp Cell Res; 2001 Nov; 271(1):152-60. PubMed ID: 11697891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [LASS2/TMSG1 gene silencing promotes the invasiveness and metastatic of human prostatic carcinoma cells through increase in vacuolar ATPase activity].
    Xu X; You J; Pei F
    Zhonghua Bing Li Xue Za Zhi; 2014 Mar; 43(3):177-83. PubMed ID: 24842017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADAM15 to α5β1 integrin switch in colon carcinoma cells: a late event in cancer progression associated with tumor dedifferentiation and poor prognosis.
    Toquet C; Colson A; Jarry A; Bezieau S; Volteau C; Boisseau P; Merlin D; Laboisse CL; Mosnier JF
    Int J Cancer; 2012 Jan; 130(2):278-87. PubMed ID: 21190186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.